Molbio Diagnostics Files for ₹12,000+ Crore IPO.

Goa-based Molbio Diagnostics, backed by Temasek and Motilal Oswal PE, has filed papers for an IPO valued at over ₹12,490 crore. The issue will include a ₹200 crore fresh issue and a large offer-for-sale (OFS) of up to 1.25 crore shares by promoters and investors. Key points: • Fresh issue: ₹200 crore, funds to be used for R&D infrastructure, new equipment at Goa & Vizag units, and general corporate needs. • OFS: Promoters and investors (including Temasek and Motilal Oswal PE) will sell a major stake. • Valuation: Based on recent adjusted issue price of ₹1,090/share, the company is valued at ₹12,490.8 crore. • Business: Known for its Truenat platform, a rapid molecular PCR test used for 30 diseases, including TB. It’s one of only two such global platforms and the only one from India—giving it strong market entry barriers. • Financials: FY25 profit surged 66% to ₹138.6 crore, while revenue rose 22% to ₹1,020.4 crore. Why it stands out: • Operates in a niche, oligopolistic diagnostics space with very high entry barriers. • Strong backing from global and domestic investors. • IPO structure shows more focus on existing shareholders exiting (OFS-heavy), while fresh issue proceeds are mainly for R&D and capacity expansion. Summary: Molbio Diagnostics is bringing a large, OFS-driven IPO at a premium valuation, built on its strong Truenat platform and growing demand for rapid molecular testing. With global-standard tech and healthy financials, it positions itself as a rare high-quality diagnostics play on Dalal Street.